A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors

Phase 1 Completed 18 enrolled Incyte Biosciences Japan GK

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability and the pharmacokinetics (PK) of INCMGA00012 (PD-1 Inhibitor), INCB001158 (Arginase Inhibitor), and the combination in Japanese participants with advanced solid tumor malignancies.

Timeline

Start: 2019-07-22
Primary completion: 2021-12-14
Completion: 2021-12-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NUMIDARGISTAT	Small molecule	75 mg	Oral
Subject	NUMIDARGISTAT	Small molecule	100 mg	Oral
Subject	NUMIDARGISTAT	Small molecule	—	—
Subject	Retifanlimab	Monoclonal antibody	500 mg	Intravenous
Subject	Retifanlimab	Monoclonal antibody	—	—

A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications